167 related articles for article (PubMed ID: 6147640)
1. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
[TBL] [Abstract][Full Text] [Related]
3. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
Carlson JA; Day TG; Botts B; Masterson BJ
Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Vermorken JB; van Lindert AC; Heintz AP; Aartsen E; van Lent M
Eur J Cancer; 1991; 27(11):1367-72. PubMed ID: 1835850
[TBL] [Abstract][Full Text] [Related]
6. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
van der Hoop RG; van der Burg ME; ten Bokkel Huinink WW; van Houwelingen C; Neijt JP
Cancer; 1990 Oct; 66(8):1697-702. PubMed ID: 2119878
[TBL] [Abstract][Full Text] [Related]
7. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Carmo-Pereira J; Costa FO; Henriques E; Ricardo JA
Cancer; 1981 Nov; 48(9):1947-51. PubMed ID: 6271386
[TBL] [Abstract][Full Text] [Related]
8. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
9. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
10. The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Posada JG; Marantz AB; Yeung KY; Smith FP; Delgado G; Edwards BK; Schein PS
Gynecol Oncol; 1985 Jan; 20(1):23-31. PubMed ID: 3917421
[TBL] [Abstract][Full Text] [Related]
11. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
Bruckner HW; Cohen CJ; Bhardwaj S; Feuer E; Chesser MR; Holland JF
Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1273-9. PubMed ID: 2509207
[TBL] [Abstract][Full Text] [Related]
12. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
Leonard RC; Smart GE; Livingstone JR; Cornbleet MA; Kerr GR; Fletcher S; Webb JN; Smyth JF
Cancer Chemother Pharmacol; 1989; 23(2):105-10. PubMed ID: 2491962
[TBL] [Abstract][Full Text] [Related]
13. CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.
Schwartz PE; Keating G; Kohorn EI; Chambers JT
Gynecol Oncol; 1986 Nov; 25(3):340-6. PubMed ID: 3096820
[TBL] [Abstract][Full Text] [Related]
14. Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience.
Bruckner HW; Cohen C; Mandeli J; Chesser MR; Kabakow B; Wallach R; Holland J
Cancer Treat Rev; 1991 Mar; 18 Suppl A():57-65. PubMed ID: 1904310
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
Lund B; Hansen M; Hansen HH; Thomsen HK; Sørensen BL; Nielsen NC; Lundvall F
Ann Oncol; 1990; 1(2):134-40. PubMed ID: 2127690
[TBL] [Abstract][Full Text] [Related]
16. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
[No Abstract] [Full Text] [Related]
17. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
[No Abstract] [Full Text] [Related]
18. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Schwartz PE; Lawrence R; Katz M
Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced ovarian cancer with sequential combination chemotherapy.
Griffin TW; Hunter RA; Cederbaum AI; Tak WK; Ward AD; Schwartz JH; Halpin TF; Strauss GM; Meyer RN; Liepman MK
Cancer; 1987 Nov; 60(9):2150-5. PubMed ID: 2830953
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
